サインイン 無料でサインアップします。

Last updated: 20 June 2022 at 4:10pm EST

Norman Selby Net Worth




The estimated Net Worth of Norman C Selby is at least 300$ dollars as of 14 May 2021. Mr. Selby owns over 5,000 units of Infinity Pharmaceuticals stock worth over 300$ and over the last 13 years he sold INFI stock worth over 0$. In addition, he makes 0$ as Lead Independent Director at Infinity Pharmaceuticals.

Mr. Selby INFI stock SEC Form 4 insiders trading

Norman has made over 4 trades of the Infinity Pharmaceuticals stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of INFI stock worth 4,600$ on 14 May 2021.

The largest trade he's ever made was exercising 5,000 units of Infinity Pharmaceuticals stock on 14 May 2021 worth over 4,600$. On average, Norman trades about 882 units every 184 days since 2012. As of 14 May 2021 he still owns at least 15,000 units of Infinity Pharmaceuticals stock.

You can see the complete history of Mr. Selby stock trades at the bottom of the page.





Norman Selby biography

Norman C. Selby serves as Lead Independent Director of the Company. Mr. Selby has spent over 35 years in the healthcare industry in various consulting, managerial, investor, and board roles. Currently, his primary focus is on two healthcare companies he helped found: Paige.AI, an artificial intelligence company focused on computational pathology where he has been a board member since May 2017, and Real Endpoints, LLC, a private healthcare information and analytics company where has been a board member since October 2010. Prior to his role at Real Endpoints, Mr. Selby served as President and Chief Executive Officer of TransForm Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, from 2001 until it was acquired by Johnson & Johnson in April 2005. Prior to TransForm Pharmaceuticals, Mr. Selby was an Executive Vice President at Citigroup/Citicorp from 1997 to 2000. Mr. Selby spent the bulk of his career, from 1978 to 1997, at McKinsey & Company where he was Director (Senior Partner) in the firm’s New York office. He held several leadership roles at McKinsey, including head of the firm’s Global Pharmaceuticals and Medical Products Practice. From 1987 to 1989, Mr. Selby took a leave of absence from McKinsey to serve as Chief Operating Officer of the New York Blood Center, the largest community blood organization in the country, where he led its financial and operational turnaround. Mr. Selby has served as a member of the board of directors of the following privately held companies: Real Endpoints LLC, since October 2010; Oppilan Pharma Ltd., a biotechnology company, since October 2016; Paige.AI since May 2017; and Escalier Biosciences, a private biotechnology company, since February 2017.



How old is Norman Selby?

Norman Selby is 68, he's been the Lead Independent Director of Infinity Pharmaceuticals since 2013. There are 3 older and 14 younger executives at Infinity Pharmaceuticals. The oldest executive at Infinity Pharmaceuticals Inc. is Anthony Evnin, 79, who is the Independent Director.

What's Norman Selby's mailing address?

Norman's mailing address filed with the SEC is C/O INFINITY PHARMACEUTICALS, INC., 1100 MASSACHUSETTS AVENUE, FLOOR 4, CAMBRIDGE, MA, 02138.

Insiders trading at Infinity Pharmaceuticals

Over the last 18 years, insiders at Infinity Pharmaceuticals have traded over 485,846,497$ worth of Infinity Pharmaceuticals stock and bought 22,639,120 units worth 175,155,554$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Partners L P/Ilbiotechnolog...、Medical Co L.P. Rosebay. On average, Infinity Pharmaceuticals executives and independent directors trade stock every 70 days with the average trade being worth of 14,976$. The most recent stock trade was executed by Adelene Q Perkins on 8 September 2023, trading 768,133 units of INFI stock currently worth 15,363$.



What does Infinity Pharmaceuticals do?

the mission of infinity pharmaceuticals, inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation. small molecule discovery and development capabilities infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation. strategic alliances building on its strengths in innovative small molecule drug discovery and development, infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline. business and scientific expertise the company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business



What does Infinity Pharmaceuticals's logo look like?

Infinity Pharmaceuticals Inc. logo

Complete history of Mr. Selby stock trades at Infinity Pharmaceuticals

日付
#
会社
 インサイダー
取引
取引
 株式 1株当たりの株価 合計金額 その後の株式数 ソース
14 May 2021 INFI Infinity Pharmaceuticals Inc. Norman C Selby
オプション行使 5,000 0.92$ 4,600$
14 May 2021
15,000 ↗
6 Mar 2014 INFI Infinity Pharmaceuticals Inc. Norman C Selby
オプション行使 2,500 8.87$ 22,175$
6 Mar 2014
10,000 ↗
14 Dec 2012 INFI Infinity Pharmaceuticals Inc. Norman C Selby
オプション行使 2,500 8.87$ 22,175$
14 Dec 2012
7,500 ↗
15 Oct 2012 INFI Infinity Pharmaceuticals Inc. Norman C Selby
オプション行使 5,000 8.87$ 44,350$
15 Oct 2012
5,000 ↗


Infinity Pharmaceuticals executives and stock owners

Infinity Pharmaceuticals executives and other stock owners filed with the SEC include: